Joinn Laboratories(China)Co.,Ltd.
603127
Rangering i aksjer
#3728
Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of... Joinn Laboratories (China) Co., Ltd. delivers a comprehensive suite of preclinical and non-clinical services to clients across the United States, China, and other international regions. The company's business is organized into three core operational areas. Its Non-Clinical Studies Services segment focuses on drug safety assessment, drug metabolism and pharmacokinetics analysis, and pharmacology and efficacy investigations. The Clinical Trial and Related Services division offers contract research organization (CRO) support for clinical trials, co-manages Phase I clinical research units, and provides bioanalytical services. Furthermore, the Sales of Research Models segment is involved in the design, production, breeding, and distribution of various research models, including non-human primates and rodents. Beyond these offerings, Joinn Laboratories also provides investment management and cell-based assay (CBA) services. Founded in 1995, the company is headquartered in Beijing, China.
Aksjekurs
$7.04
Markedsverdi
$4.50B
Endring (1 dag)
-2.00%
Endring (1 år)
185.59%
Land
CN
Handel Joinn Laboratories(China)Co.,Ltd. (603127)
Kategori
Healthcare
Inntekter for Joinn Laboratories(China)Co.,Ltd. (603127)
Inntekter i 2026 TTM: 0
Ifølge Joinn Laboratories(China)Co.,Ltd. sine nyeste økonomiske rapporter er selskapets nåværende resultat 0. I 2026 hadde selskapet et resultat på 0, lik resultatet i 2026, som var 0. Resultatet som vises på denne siden er resultat før renter og skatt, eller EBIT.
Inntektshistorikk for Joinn Laboratories(China)Co.,Ltd. fra 2026 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| Ikke nok data for de angitte datoene. | ||
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| $7.61B | - |
US
|
|
| $4.76B | - |
US
|
|
| $-252.70M | - |
US
|
|
| - | - |
CN
|
|
| $1.66B | - |
US
|
